Evidence map›Paper›PMID 34575587›Full record

ArticlePharmaceutics2021

Graphene Oxide and Graphene Quantum Dots as Delivery Systems of Cationic Porphyrins: Photo-Antiproliferative Activity Evaluation towards T24 Human Bladder Cancer Cells.

Luca Menilli, Ana R Monteiro, Silvia Lazzarotto, Filipe M P Morais, Ana T P C Gomes, Nuno M M Moura, Sara Fateixa, Maria A F Faustino, Maria G P M S Neves, Tito Trindade and 1 more

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Molecules (Basel, Switzerland) · 2023
    Article
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Luca MenilliDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.ORCID 0000-0003-2774-6411
Ana R MonteiroCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0003-2528-943X
Silvia LazzarottoDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.
Filipe M P MoraisLAQV-Requimte, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.
Ana T P C GomesCESAM, Department of Biology, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0002-3201-0081
Nuno M M MouraLAQV-Requimte, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0002-9373-7006
Sara FateixaCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0001-5958-466X
Maria A F FaustinoLAQV-Requimte, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0003-4423-3802
Maria G P M S NevesLAQV-Requimte, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0002-7953-8166
Tito TrindadeCICECO-Aveiro Institute of Materials, Department of Chemistry, University of Aveiro, 3810-193 Aveiro, Portugal.ORCID 0000-0002-5456-7243
Giorgia MioloDepartment of Pharmaceutical and Pharmacological Sciences, University of Padova, 35131 Padova, Italy.ORCID 0000-0003-1095-7124
University of Aveiro · PTUniversity of Padua · ITUniversidade Católica Portuguesa · PT

Funding

Fundação para a Ciência e a Tecnologia REF.-048-88-ARH/2018Fundação para a Ciência e a Tecnologia REF.-069-88-ARH/2018Fundação para a Ciência e a Tecnologia Ref.UIDB/50006/2020Fundação para a Ciência e a Tecnologia Ref.UID/CTM/50011/2020Fundação para a Ciência e a Tecnologia SFRH/BD/137356/2018Università degli Studi di Padova CPDA150854
6 · The paper itself

Abstract

The development of new photodynamic therapy (PDT) agents designed for bladder cancer (BC) treatments is of utmost importance to prevent its recurrence and progression towards more invasive forms. Here, three different porphyrinic photosensitizers (PS) (TMPyP, Zn-TMPyP, and P1-C

Indexed as

bladder cancercationic porphyrinsgraphene oxidegraphene quantum dotsnon-covalent hybridsphotodynamic therapy

Identifiers

PMID34575587
PMCPMC8470602
OpenAlexW3199122752

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.